Cellceutix has acquired the rights to the compound KM 732, which shows properties in the reduction of high blood pressure.
Preliminary testing in rats revealed that test animals showed a significant decrease in both systolic and diastolic blood pressure, as compared to controls with no apparent toxicity.
Reportedly, the clinical observation of the animals indicated that blood pressure was reduced within a few minutes of the administration of the compound.
The company plans to conduct proof of concept studies in large animals to evaluate the compound’s potential for development to treat hypertensive emergency.
George Evans, CEO of Cellceutix, said: Hypertensive emergency is a serious condition affecting over 500,000 Americans per year, thus warranting our early investigational efforts into KM732.